Get the Weekly Intelligence Brief — top committee picks every Sunday.
TEVA · NYSE · STOCK

Teva Pharmaceutical Industries Limited

Healthcare Updated August 11, 2026
$36.49
52W $16.26 – $37.35
55/100
$42.49B
57.2
0.86
AI Committee Verdict
Watch
55/100
Conviction: Contested · 50% agreement · 6 analysts
Contested

Is TEVA Bullish or Bearish?

Mixed. Innellis AI committee rates Teva Pharmaceutical Industries Limited (TEVA) Watch with a composite score of 55/100 , based on 6 analysts with 50% agreement. Last updated August 11, 2026.

What Would Change This View

Upgrade to Buy
Requires a committee score of 60.0 — +4.98 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Reduce
Requires the score to fall below 40.0 — -15.02 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is genuinely divided. News Analyst sees a compelling case — news sentiment is positive (+0.63 across 21 articles, 14d). Value Analyst remains cautious — p/e of 57.5 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.

Bull & Bear Case

Bull Case
  • Price structure making higher highs and higher lows — Technical
  • MACD histogram positive -- bullish momentum — Technical
  • Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
  • VIX regime is low -- calm backdrop supports risk-taking — Macro
  • Market regime is bullish (Bull market -- normal position sizing) — Macro
  • News sentiment is positive (+0.63 across 21 articles, 14d) — News
Bear Case
  • P/E of 57.5 is expensive by classic value standards — Value
  • Price-to-book of 4.9x prices in significant intangible value — Value
  • Debt-to-equity of 2.12 adds balance-sheet risk to the value case — Value
  • RSI at 78 is in overbought territory — Technical
  • High leverage (debt-to-equity 2.12) amplifies downside in a stress scenario — Risk
  • Bollinger bandwidth of 25.0% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of August 11, 2026
Overall Committee Score
55/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 81%
of 192 Healthcare peers
Value Analyst bearish
28 / 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− P/E of 57.5 is expensive by classic value standards
Growth Analyst bearish
40 / 100 · Low confidence
Growth story is weak, decelerating, or inconsistent
Technical Analyst bullish
61 / 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− RSI at 78 is in overbought territory
Risk Analyst neutral
45 / 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
− High leverage (debt-to-equity 2.12) amplifies downside in a stress scenario
Macro Analyst bullish
78 / 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst bullish
78 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.63 across 21 articles, 14d)
Portfolio Manager neutral
55 / 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Open Full Terminal →

Technical Analysis

RSI (14)
77.8
Overbought
MACD Histogram
0.423
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Mixed
Support
$30.81
Resistance
$36.99
Bollinger %B
0.89
Inside Bands
Price vs Moving Averages
EMA 9
$35.04 Above
EMA 21
$34.04 Above
EMA 50
$33.52 Above
EMA 200
$30.44 Above

Fundamental Analysis

Valuation
46
Profitability
56
Financial Health
12
Cash Flow
70
Valuation
P/E Ratio 57.2×
P/B Ratio 5.50×
PEG Ratio 0.10
Dividend Yield 0.00%
52W High $37.35
52W Low $16.26
Quality & Growth
ROE 1782.6%
ROA 346.0%
Gross Margin 5245.8%
Operating Margin 1710.8%
Revenue Growth YoY
Debt / Equity 2.16
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of 57.2 (rich relative to a 15-40x range); Price-to-book of 5.5x; PEG ratio of 0.1 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 17.8%; Return on assets of 3.5%; Net margin of 4.2%; Gross margin of 52.5%; Current ratio of 0.88 (tight short-term liquidity); Debt-to-equity of 2.16; Free cash flow per share is positive (2.04); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full TEVA Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →

Explore TEVA Further

📈 Rating History 💰 Earnings 📰 Recent Events 🔄 What Changed 📖 Thesis Evolution 🔍 Similar Stocks
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime